Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer

In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartarone, Alfredo, Lapadula, Vittoria, Di Micco, Concetta, Rossi, Gemma, Ottanelli, Carlotta, Marini, Andrea, Giorgione, Roberta, Ferrari, Katia, Catalano, Martina, Voltolini, Luca, Mini, Enrico, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176852/
https://www.ncbi.nlm.nih.gov/pubmed/34094913
http://dx.doi.org/10.3389/fonc.2021.632256
_version_ 1783703316044185600
author Tartarone, Alfredo
Lapadula, Vittoria
Di Micco, Concetta
Rossi, Gemma
Ottanelli, Carlotta
Marini, Andrea
Giorgione, Roberta
Ferrari, Katia
Catalano, Martina
Voltolini, Luca
Mini, Enrico
Roviello, Giandomenico
author_facet Tartarone, Alfredo
Lapadula, Vittoria
Di Micco, Concetta
Rossi, Gemma
Ottanelli, Carlotta
Marini, Andrea
Giorgione, Roberta
Ferrari, Katia
Catalano, Martina
Voltolini, Luca
Mini, Enrico
Roviello, Giandomenico
author_sort Tartarone, Alfredo
collection PubMed
description In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations.
format Online
Article
Text
id pubmed-8176852
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81768522021-06-05 Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer Tartarone, Alfredo Lapadula, Vittoria Di Micco, Concetta Rossi, Gemma Ottanelli, Carlotta Marini, Andrea Giorgione, Roberta Ferrari, Katia Catalano, Martina Voltolini, Luca Mini, Enrico Roviello, Giandomenico Front Oncol Oncology In the last few years the advent of targeted therapies against oncogenic drivers significantly improved the survival of non small cell lung cancer (NSCLC) patients with a favourable toxicity profile. Therefore, genetic testing, including at least EGFR mutations and ALK/ROS1 rearrangements, should be performed in all NSCLC patients (in particular with adenocarcinoma) who received a diagnosis of advanced disease. This review focuses on novel druggable oncogenic drivers, such as MET exon 14 mutations/MET amplification, RET fusions, BRAF V600E mutations, KRAS G12C mutations, NTRK rearrangements, and HER2 alterations. Frontiers Media S.A. 2021-05-21 /pmc/articles/PMC8176852/ /pubmed/34094913 http://dx.doi.org/10.3389/fonc.2021.632256 Text en Copyright © 2021 Tartarone, Lapadula, Di Micco, Rossi, Ottanelli, Marini, Giorgione, Ferrari, Catalano, Voltolini, Mini and Roviello https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Tartarone, Alfredo
Lapadula, Vittoria
Di Micco, Concetta
Rossi, Gemma
Ottanelli, Carlotta
Marini, Andrea
Giorgione, Roberta
Ferrari, Katia
Catalano, Martina
Voltolini, Luca
Mini, Enrico
Roviello, Giandomenico
Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
title Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
title_full Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
title_fullStr Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
title_full_unstemmed Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
title_short Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer
title_sort beyond conventional: the new horizon of targeted therapy for the treatment of advanced non small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176852/
https://www.ncbi.nlm.nih.gov/pubmed/34094913
http://dx.doi.org/10.3389/fonc.2021.632256
work_keys_str_mv AT tartaronealfredo beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT lapadulavittoria beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT dimiccoconcetta beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT rossigemma beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT ottanellicarlotta beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT mariniandrea beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT giorgioneroberta beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT ferrarikatia beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT catalanomartina beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT voltoliniluca beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT minienrico beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer
AT roviellogiandomenico beyondconventionalthenewhorizonoftargetedtherapyforthetreatmentofadvancednonsmallcelllungcancer

Ejemplares similares